ORMP
Price
$2.38
Change
-$0.11 (-4.42%)
Updated
Dec 20, 04:59 PM (EDT)
66 days until earnings call
UBX
Price
$0.95
Change
-$0.02 (-2.06%)
Updated
Dec 20, 04:59 PM (EDT)
Ad is loading...

ORMP vs UBX

Header iconORMP vs UBX Comparison
Open Charts ORMP vs UBXBanner chart's image
Oramed Pharmaceuticals
Price$2.38
Change-$0.11 (-4.42%)
Volume$2.34K
CapitalizationN/A
Unity Biotechnology
Price$0.95
Change-$0.02 (-2.06%)
Volume$322
CapitalizationN/A
ORMP vs UBX Comparison Chart
Loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ORMP vs. UBX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Hold and UBX is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (ORMP: $2.37 vs. UBX: $0.96)
Brand notoriety: ORMP and UBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORMP: 66% vs. UBX: 153%
Market capitalization -- ORMP: $95.94M vs. UBX: $16.17M
ORMP [@Biotechnology] is valued at $95.94M. UBX’s [@Biotechnology] market capitalization is $16.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORMP’s FA Score shows that 0 FA rating(s) are green whileUBX’s FA Score has 0 green FA rating(s).

  • ORMP’s FA Score: 0 green, 5 red.
  • UBX’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than UBX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORMP’s TA Score shows that 3 TA indicator(s) are bullish while UBX’s TA Score has 4 bullish TA indicator(s).

  • ORMP’s TA Score: 3 bullish, 7 bearish.
  • UBX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, UBX is a better buy in the short-term than ORMP.

Price Growth

ORMP (@Biotechnology) experienced а -4.05% price change this week, while UBX (@Biotechnology) price change was -14.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ORMP is expected to report earnings on Feb 26, 2025.

UBX is expected to report earnings on May 09, 2023.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($95.9M) has a higher market cap than UBX($16.2M). ORMP YTD gains are higher at: 2.597 vs. UBX (-50.269). ORMP has higher annual earnings (EBITDA): 9.44M vs. UBX (-20.99M). ORMP has more cash in the bank: 142M vs. UBX (29M). ORMP has less debt than UBX: ORMP (429K) vs UBX (20.7M). ORMP (0) and UBX (0) have equivalent revenues.
ORMPUBXORMP / UBX
Capitalization95.9M16.2M592%
EBITDA9.44M-20.99M-45%
Gain YTD2.597-50.269-5%
P/E Ratio21.64N/A-
Revenue00-
Total Cash142M29M490%
Total Debt429K20.7M2%
FUNDAMENTALS RATINGS
ORMP vs UBX: Fundamental Ratings
ORMP
UBX
OUTLOOK RATING
1..100
7254
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8498
PRICE GROWTH RATING
1..100
4989
P/E GROWTH RATING
1..100
48100
SEASONALITY SCORE
1..100
n/a42

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UBX's Valuation (47) in the Biotechnology industry is in the same range as ORMP (67) in the Pharmaceuticals Other industry. This means that UBX’s stock grew similarly to ORMP’s over the last 12 months.

UBX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that UBX’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (84) in the Pharmaceuticals Other industry is in the same range as UBX (98) in the Biotechnology industry. This means that ORMP’s stock grew similarly to UBX’s over the last 12 months.

ORMP's Price Growth Rating (49) in the Pharmaceuticals Other industry is somewhat better than the same rating for UBX (89) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than UBX’s over the last 12 months.

ORMP's P/E Growth Rating (48) in the Pharmaceuticals Other industry is somewhat better than the same rating for UBX (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than UBX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORMPUBX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 27 days ago
76%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
71%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DRTTF0.620.04
+6.72%
Dirtt Environmental Solutions Ltd
IPXHY12.450.20
+1.63%
Inpex Corp.
LZAGF587.152.77
+0.47%
Lonza Group AG
SPKKY7.920.01
+0.13%
Spark New Zealand Limited
CYTOF0.12-0.18
-60.07%
Altamira Therapeutics Ltd

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BPMC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BPMC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-4.82%
BPMC - ORMP
44%
Loosely correlated
+1.36%
BTAI - ORMP
44%
Loosely correlated
+8.12%
INO - ORMP
44%
Loosely correlated
-0.27%
MBIO - ORMP
44%
Loosely correlated
+1.64%
VERV - ORMP
44%
Loosely correlated
+11.24%
More

UBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, UBX has been loosely correlated with NCNA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if UBX jumps, then NCNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UBX
1D Price
Change %
UBX100%
-1.04%
NCNA - UBX
42%
Loosely correlated
N/A
ABSI - UBX
33%
Poorly correlated
+2.40%
ASMB - UBX
33%
Poorly correlated
-3.80%
ORMP - UBX
33%
Poorly correlated
-4.82%
MDGL - UBX
32%
Poorly correlated
+5.12%
More